Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLAP: Camrelizumab + Apatinib in Advanced Cervical Cancer
NCT03816553Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2019
- Primary completion
- Apr 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in Cervical Cancer (CC), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate at 12 months. Started Jan 2019; status: completed.
02
Drugs
camrelizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03816553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03816553.